Cisatracurium Besylate Injection
Product Images NDC 70069-161

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Cisatracurium Besylate (NDC 70069-161). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Somerset Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

44d631f0 2b8c 4df7 B3ba 46ed00cd710b 01

Chemical structure diagram of Cisatracurium Besylate, illustrating its molecular components and connectivity, including aromatic rings, methoxy groups, and a bis-quaternary ammonium framework linked by an ester and a benzene sulfonate (besylate) group.*

FDA Label Image

44d631f0 2b8c 4df7 B3ba 46ed00cd710b 02

Scatter plot chart showing data points comparing heart rate (HR) changes on the vertical axis with mean arterial pressure (MAP) changes on the horizontal axis, each axis ranging from -60% to +60%. The plot appears to illustrate variability or correlation between HR and MAP values.*

FDA Label Image

44d631f0 2b8c 4df7 B3ba 46ed00cd710b 03

A scatter plot chart depicting data points distributed around intersecting axes labeled with percentage changes. The vertical axis is labeled 'HR' with increments from -60% to +60%, and the horizontal axis is labeled 'MAP' also ranging from -60% to +60%. The data points are scattered near the center of the graph.*

FDA Label Image

44d631f0 2b8c 4df7 B3ba 46ed00cd710b 04

Label for Cisatracurium Besylate Injection, USP, 20 mg/10 mL (2 mg/mL) in a 10 mL multiple-dose vial. The label includes warnings indicating it is a paralyzing agent requiring facilities for artificial respiration. Contains 0.9% benzyl alcohol as a preservative. Manufactured for Somerset Therapeutics, LLC, Hollywood, FL, made in India. Storage instructions and barcode are also shown.*

FDA Label Image

44d631f0 2b8c 4df7 B3ba 46ed00cd710b 05

The packaging label for Cisatracurium Besylate Injection, USP, 2 mg/mL (20 mg/10 mL) intravenous injection by Somerset Therapeutics, LLC. The label indicates a 10 mL multiple-dose vial, with warnings about its paralyzing effects and the need for facilities to have artificial respiration available. It includes storage instructions, ingredient details, and labeling for 0.9% benzyl alcohol as a preservative. Manufactured for Somerset Therapeutics, made in India.*

FDA Label Image

44d631f0 2b8c 4df7 B3ba 46ed00cd710b 06

Label for Cisatracurium Besylate Injection, USP 20 mg/10 mL (2 mg/mL) by Somerset Therapeutics LLC. The label states the product is a sterile, nonpyrogenic intravenous injection supplied in multiple-dose vials. It includes warnings for paralysis risk and respiratory arrest, and notes 0.9% benzyl alcohol as a preservative. The label also provides storage instructions and manufacturing details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.